By Professor David Goldstein

Journal articles

Chantrill L; Goldstein D, 2016, 'Pancreatic cancer', Cancer Forum, 40, pp. 3 - 5

McLachlan SA; Fisher RJ; Zalcberg J; Solomon M; Burmeister B; Goldstein D; Leong T; Ackland SP; McKendrick J; McClure B; MacKay J; Ngan SY, 2016, 'The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)', European Journal of Cancer, 55, pp. 15 - 26, http://dx.doi.org/10.1016/j.ejca.2015.10.060

Wang X; Goldstein D; Crowe P; Yang M; Garrett K; Zeps N; Yang JL, 2016, 'Overcoming resistance of targeted egfr monotherapy by inhibition of stat3 escape pathway in soft tisue sarcoma', Oncotarget, 7, pp. 21496 - 21509, http://dx.doi.org/10.18632/oncotarget.7452

Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV, 2016, 'Hepatocyte growth factor inhibition: A novel therapeutic approach in pancreatic cancer', British Journal of Cancer, 114, pp. 269 - 280, http://dx.doi.org/10.1038/bjc.2015.478

Goldstein D; Chiorean EG; Tabernero J; El-Maraghi RH; Ma WW; Reni M; Harris M; Whorf RC; Coughlin S; Li J; Manax VG; Lu BD; Romano A; Von Hoff DD, 2016, 'Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).', Journal of Clinical Oncology, 34, pp. 333 - 333, http://dx.doi.org/10.1200/jco.2016.34.4_suppl.333

Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC, 2016, 'Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial', BMC Cancer, 16, pp. 22, http://dx.doi.org/10.1186/s12885-016-2051-5

O’Callaghan C; Schofield P; Butow P; Nolte L; Price M; Tsintziras S; Sze M; Thein T; Yiu D; Mireskandari S; Goldstein D; Jefford M, 2016, '“I might not have cancer if you didn’t mention it”: a qualitative study on information needed by culturally diverse cancer survivors', Supportive Care in Cancer, 24, pp. 409 - 418, http://dx.doi.org/10.1007/s00520-015-2811-9

Sharbeen G; McCarroll J; Liu J; Youkhana J; Limbri LF; Biankin AV; Johns A; Kavallaris M; Goldstein D; Phillips PA, 2016, 'Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids', Neoplasia (United States), 18, pp. 753 - 764, http://dx.doi.org/10.1016/j.neo.2016.10.011

Goldstein D; Von Hoff DD; Moore M; Greeno E; Tortora G; Ramanathan RK; Macarulla T; Liu H; Pilot R; Ferrara S; Lu B, 2016, 'Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)', European Journal of Cancer, 52, pp. 85 - 91, http://dx.doi.org/10.1016/j.ejca.2015.10.017

Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L, 2016, 'Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?', European Journal of Cancer, 53, pp. 96 - 104, http://dx.doi.org/10.1016/j.ejca.2015.10.006

Pothula SP; Xu Z; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2016, 'Key role of pancreatic stellate cells in pancreatic cancer', Cancer Letters, http://dx.doi.org/10.1016/j.canlet.2015.10.035

Bridgewater J; Lopes A; Wasan H; Malka D; Jensen L; Okusaka T; Knox J; Wagner D; Cunningham D; Shannon J; Goldstein D; Moehler M; Bekaii-Saab T; McNamara MG; Valle JW, 2016, 'Prognostic factors for progression-free and overall survival in advanced biliary tract cancer', Annals of Oncology, 27, pp. 134 - 140, http://dx.doi.org/10.1093/annonc/mdv483

McCarroll JA; Teo J; Boyer C; Youkhana J; Sagnella S; Duong H; Sharbeen G; Goldstein D; Davis T; Kavallaris M; Phillips P; Liu J, 2016, 'A rationally optimized nanoparticle system for the delivery of RNA interference therapeutics into pancreatic tumors in vivo.', Biomacromolecules, 17, pp. 2337 - 2351, http://dx.doi.org/10.1021/acs.biomac.6b00185

Beesley VL; Janda M; Goldstein D; Gooden H; Merrett ND; O'Connell DL; Rowlands IJ; Wyld D; Neale RE, 2016, 'A tsunami of unmet needs: Pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services', Psycho-Oncology, 25, pp. 150 - 157, http://dx.doi.org/10.1002/pon.3887

Sharbeen G; Youkhana J; McCarroll J; Akerman A; Goldstein D; Phillips P, 2016, 'MutY-Homolog modulates pancreatic cancer cell survival and chemoresistance', Pancreatology, 16, pp. S5 - S5, http://dx.doi.org/10.1016/j.pan.2016.05.024

Oar AJ; Wong W; Chen C; Haghighi KS; Thompson S; Goldstein D, 2016, 'Stereotactic body hypofractionated radiotherapy for inoperable pancreatic cancer, with or without metastases', HPB, 18, pp. e359 - e359, http://dx.doi.org/10.1016/j.hpb.2016.02.932

Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; Van Der Graaf WTA; Zalcberg JR; Litière S; Blay JY, 2015, 'Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas', Journal of Clinical Oncology, 33, pp. 4276 - 4283, http://dx.doi.org/10.1200/JCO.2015.62.4304

Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI, 2015, 'Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients', British Journal of Cancer, 113, pp. 1571 - 1580, http://dx.doi.org/10.1038/bjc.2015.368

Chandrasegaram MD; Goldstein D; Simes J; Gebski V; Kench JG; Gill AJ; Samra JS; Merrett ND; Richardson AJ; Barbour AP; Fawcett J; Grimison PS; Christophi C; Padbury R; Haghighi KS; Chen JW; Nikfarjam M; O'Rourke N; Spry N, 2015, 'Meta-analysis of radical resection rates and margin assessment in pancreatic cancer', British Journal of Surgery, 102, pp. 1459 - 1472, http://dx.doi.org/10.1002/bjs.9892

Goldstein D; Fawcett J; Bridgewater J; Choti M; Wilson K; Gebski V; Aiken C; Eminton Z; Falk S; Stanton L; Primrose J, 2015, 'Feasibility of trials to assess safety and toxicity of peri-operative and post-operative adjuvant therapy for hepatic metastases from colorectal cancer', EUROPEAN JOURNAL OF CANCER, 51, pp. S343 - S343, http://dx.doi.org/10.1016/S0959-8049(16)30967-4

Stein A; Arnold D; Bridgewater J; Goldstein D; Jensen LH; Klümpen HJ; Lohse AW; Nashan B; Primrose J; Schrum S; Shannon J; Vettorazzi E; Wege H, 2015, 'Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial', BMC Cancer, 15, pp. 564, http://dx.doi.org/10.1186/s12885-015-1498-0

Jaeger U; Trneny M; Melzer H; Praxmarer M; Nawarawong W; Yehuda DB; Goldstein D; Mihaljevic B; Ilhan O; Ballova V; Hedenus M; Hsiao LT; Au WY; Burgstaller S; Weidinger G; Keil F; Dittrich C; Skrabs C; Klingler A; Chott A; Fridrik MA; Greil R, 2015, 'Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: Results of the randomized NHL13 trial', Haematologica, 100, pp. 955 - 963, http://dx.doi.org/10.3324/haematol.2015.125344

Apte MV; Xu Z; Pothula S; Goldstein D; Pirola RC; Wilson JS, 2015, 'Pancreatic cancer: The microenvironment needs attention too!', Pancreatology, 15, pp. S32 - S38, http://dx.doi.org/10.1016/j.pan.2015.02.013

Davis ID; Long A; Yip S; Espinoza D; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Harvie R; Jovanovic L; Hudson AL; Nelson CC; Stockler MR; Martin A, 2015, 'EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma', Annals of Oncology, 26, pp. 1118 - 1123, http://dx.doi.org/10.1093/annonc/mdv078

Sandler C; Goldstein D; Horsfield S; Bennett BK; Friedlander M; Bastick PA; Lewis CR; Segelov E; Boyle FM; Chin MTM; Barry BK; Webber K; Lloyd AR, 2015, 'TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.', Journal of Clinical Oncology, 33, pp. 9571 - 9571, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9571

Pantaleo MA; Lolli C; Nannini M; Astolfi A; Indio V; Saponara M; Urbini M; La Rovere S; Gill A; Goldstein D; Ceccarelli C; Santini D; Rossi G; Fiorentino M; Di Scioscio V; Fusaroli P; Mandrioli A; Gatto L; Catena F; Basso U; Ercolani G; Pinna AD; Biasco G, 2015, 'Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations', Genetics in Medicine, 17, pp. 391 - 395, http://dx.doi.org/10.1038/gim.2014.115

Lee CK; Goldstein D; Gibbs E; Joensuu H; Zalcberg J; Verweij J; Casali PG; Maki RG; Cioffi A; McArthur G; Lord SJ; Yip D; Kanjanapan Y; Rutkowski P, 2015, 'Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib', European Journal of Cancer, 51, pp. 852 - 860, http://dx.doi.org/10.1016/j.ejca.2015.02.015

Tebbutt N; Kotasek D; Burris HA; Schwartzberg LS; Hurwitz H; Stephenson J; Warner DJ; Chen L; Hsu CP; Goldstein D, 2015, 'Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer', Cancer Chemotherapy and Pharmacology, 75, pp. 993 - 1004, http://dx.doi.org/10.1007/s00280-015-2694-y

Sharbeen G; McCarroll J; Goldstein D; Phillips PA, 2015, 'Exploiting Base Excision Repair to Improve Therapeutic Approaches for Pancreatic Cancer', Frontiers in Nutrition, 2, pp. 10, http://dx.doi.org/10.3389/fnut.2015.00010

Sze M; Butow P; Bell M; Vaccaro L; Dong S; Eisenbruch M; Jefford M; Girgis A; King M; McGrane J; Ng W; Asghari R; Parente P; Liauw W; Goldstein D; Psycho-oncology Co-operative Research Group Culturally and Linguistically Diverse (CALD) TEAM , 2015, 'Migrant health in cancer: outcome disparities and the determinant role of migrant-specific variables', Oncologist, 20, pp. 523 - 531, http://dx.doi.org/10.1634/theoncologist.2014-0274

Chan DL; Goldstein D; Zalcberg JR, 2015, 'Neuroendocrine tumours - Models for rare tumour management', Cancer Forum, 39, pp. 13 - 16

Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD, 2015, 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial', Journal of the National Cancer Institute, 107, http://dx.doi.org/10.1093/jnci/dju413

Murphy C; Sabesan S; Steer C; Yates P; Booms A; Jones V; Simpson A; Clarke K; Eek R; Ashley D; Goldstein D; Packer C; Tuthill F; Boyce A; Underhill C, 2015, 'Oncology service initiatives and research in regional Australia', Australian Journal of Rural Health, 23, pp. 40 - 48, http://dx.doi.org/10.1111/ajr.12173

Wang X; Batty KM; Crowe PJ; Goldstein D; Yang JL, 2015, 'The Potential of panHER Inhibition in Cancer', Frontiers in Oncology, 5, pp. 2, http://dx.doi.org/10.3389/fonc.2015.00002

Pavlakis N; Sjoquist KM; Tsobanis E; Martin A; Kang Y-K; Bang Y-J; O'Callaghan CJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Burnell MJ; Alcindor T; Strickland A; Wong M; Kim JW; Simes J; Zalcberg JR; Goldstein D, 2015, 'INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)-A study by the Australasian Gastrointestinal Trials Group (AGITG), first results', JOURNAL OF CLINICAL ONCOLOGY, 33, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.9

Vernerey D; Hammel P; Paget-Bailly S; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Moore MJ; André T; Mineur L; Chibaudel B; Louvet C; Bonnetain F, 2015, 'Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.', Journal of Clinical Oncology, 33, pp. 235 - 235, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.235

Kunzmann V; Ramanathan RK; Goldstein D; Penenberg DN; Ferrara S; Lu B; Von Hoff DD, 2015, 'Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.', Journal of Clinical Oncology, 33, pp. 382 - 382, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.382

Tabernero J; Gabrielachiorean E; Infante JR; Hingorani SR; Ganju V; Weekes C; Scheithauer W; Ramanathan RK; Goldstein D; Penenberg DN; Romano A; Ferrara S; Von Hoff DD, 2015, 'Prognostic factorsofsurvival inarandomizedphaseIIItrial (MPACT)of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer', Oncologist, 20, pp. 143 - 150, http://dx.doi.org/10.1634/theoncologist.2014-0394

Vajdic CM; Goldstein D, 2015, 'Cancer of unknown primary site', Australian Family Physician, 44, pp. 640 - 643

Burmeister EA; O'Connell DL; Beesley VL; Goldstein D; Gooden HM; Janda M; Jordan SJ; Merrett ND; Payne ME; Wyld D; Neale RE, 2015, 'Describing patterns of care in pancreatic cancer a population-based study', Pancreas, 44, pp. 1259 - 1265, http://dx.doi.org/10.1097/MPA.0000000000000384

McCarroll JA; Sharbeen G; Liu J; Youkhana J; Goldstein D; McCarthy N; Limbri LF; Dischl D; Ceyhan GO; Erkan M; Johns AL; Biankin AV; Kavallaris M; Phillips PA; Johns A, 2015, 'βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer', Oncotarget, 6, pp. 2235 - 2249, http://dx.doi.org/10.18632/oncotarget.2946

Neale R; Burmeister E; O'Connell D; Beesley V; Goldstein D; Gooden H; Janda M; Jordan S; Merrett N; Payne M; Wyld D, 2015, 'Describing patterns of care in pancreatic cancer – A population-based study', Pancreatology, 15, pp. S83 - S83, http://dx.doi.org/10.1016/j.pan.2015.05.306

Burmeister E; Jordan S; O'Connell D; Beesley V; Goldstein D; Gooden H; Janda M; Merrett N; Wyld D; Neale R, 2015, 'Determinants of attempted resection for patients with non-metastatic pancreatic cancer', Pancreatology, 15, pp. S84 - S85, http://dx.doi.org/10.1016/j.pan.2015.05.312

Neale R; Waterhouse M; Burmeister E; Ballard E; O'Connell D; Beesley V; Goldstein D; Gooden H; Janda M; Jordan S; Merrett N; Payne M; Wyld D, 2015, 'Determinants of outcomes following resection for pancreatic cancer – An Australian population-based study', Pancreatology, 15, pp. S85 - S85, http://dx.doi.org/10.1016/j.pan.2015.05.313

Pavlakis N; Sjoquist KM; Tsobanis E; Martin AJ; Kang Y-K; Bang Y-J; O'Callaghan CJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Burnell MJ; Alcindor T; Strickland A; Kim JW; Yip S; Simes J; Zalcberg JR; Goldstein D, 2015, 'LBA-06 INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results', Annals of Oncology, 26, pp. iv119 - iv119, http://dx.doi.org/10.1093/annonc/mdv262.06

Tempero M; Cardin D; Biankin A; Goldstein D; Moore M; O'Reilly E; Philip P; Riess H; Macarulla T; Yung L; Li M; Lu B, 2015, 'P-185 Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT', Annals of Oncology, 26, pp. iv54 - iv54, http://dx.doi.org/10.1093/annonc/mdv233.185

Vernerey D; Goldstein D; Huguet F; Paget-Bailly S; Van Laethem J-L; Glimelius B; Artru P; Moore MJ; André T; Mineur L; Chibaudel B; Louvet C; Hammel P; Bonnetain F, 2015, 'Prognostic score and nomogram to predict overall survival in locally advanced pancreatic cancer', Pancreatology, 15, pp. S107 - S107, http://dx.doi.org/10.1016/j.pan.2015.05.383

Goldstein D; Giver M; Chakraborty B, 2015, 'Synchronization patterns in geometrically frustrated rings of relaxation oscillators.', Chaos, 25, pp. 123109, http://dx.doi.org/10.1063/1.4936246

Tempero M; Cardin D; Biankin AV; Goldstein D; Moore M; O'Reilly E; Philip P; Riess H; Macarulla T; Yung L; Li M; Lu B, 2015, 'Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)', Gastroenterology, 148, pp. S - 944, http://dx.doi.org/10.1016/s0016-5085(15)33220-0

Park SB; Kwok JB; Loy CT; Friedlander ML; Lin CSY; Krishnan AV; Lewis CR; Kiernan MC; Goldstein D, 2014, 'Paclitaxel-induced neuropathy: Potential association of MAPT and GSK3B genotypes', BMC Cancer, 14, pp. 993, http://dx.doi.org/10.1186/1471-2407-14-993

Back to profile page